Aegis Capital initiated coverage on XOMA with a new price target
$XOMA
Biotechnology: Pharmaceutical Preparations
Health Care
Aegis Capital initiated coverage of XOMA with a rating of Buy and set a new price target of $60.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/17/2025 | $35.00 | Buy | The Benchmark Company |
| 4/29/2024 | $40.00 | Outperform | Leerink Partners |
| 10/8/2021 | $56.00 → $69.00 | Buy | HC Wainwright & Co. |
| 9/9/2021 | $60.00 → $56.00 | Buy | Aegis Capital |
| 9/7/2021 | $22.00 | Outperform → Neutral | Wedbush |
| 9/7/2021 | $22.00 | Neutral → Underperform | Wedbush |
| 6/29/2021 | $60.00 | Buy | Aegis Capital |
8-K - XOMA Royalty Corp (0000791908) (Filer)
10-Q - XOMA Royalty Corp (0000791908) (Filer)
8-K - XOMA Royalty Corp (0000791908) (Filer)